A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

NCT04343989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

178

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Clazakizumab 25 mg
DRUG: Clazakizumab 12.5 mg
OTHER: Placebo

Sponsor

NYU Langone Health